Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31114862 | 1.00 | TACR1 (0.32) | TACR1HCRTR1HCRTR2KDM4EHPGD | |
| SCHEMBL22506459 | 0.94 | CYP3A4 (0.36) | TACR1CNR1CYP3A4 | |
| SCHEMBL20101205 | 0.94 | CYP3A4 (0.36) | TACR1CNR1CYP3A4 | |
| SCHEMBL20101202 | 0.90 | PPARA (0.32) | KDM4EHPGDHSD17B10TP53CYP3A4 | |
| SCHEMBL20101200 | 0.90 | PPARA (0.32) | KDM4EHPGDHSD17B10TP53CYP3A4 | |
| SCHEMBL20030665 | 0.89 | NPSR1 (0.33) | KDM4EHPGDHSD17B10TP53CYP3A4 | |
| SCHEMBL23100103 | 0.88 | TP53 (0.31) | KDM4EHPGDHSD17B10TP53CYP3A4 | |
| SCHEMBL20101153 | 0.88 | CNR1 (0.34) | TACR1KDM4EHPGDHSD17B10CNR1 | |
| SCHEMBL20101151 | 0.88 | PDE2A (0.30) | TP53CYP3A4 | |
| SCHEMBL20030860 | 0.88 | TP53 (0.30) | TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210078991-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2021-03-18 | — | — | US | disclosed |
| US-10800772-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20180118734-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-03 | — | — | US | disclosed |
| US-20180118734-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800772-B2 | Therapeutic compounds | NQO1, HAVCR2, CCR5 | TACR1 570/4885HCRTR1 3644/4885HCRTR2 4127/4885 |
| US-20210078991-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | TACR1 570/4885HCRTR1 3644/4885HCRTR2 4127/4885 |
| US-20180118734-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | TACR1 570/4885HCRTR1 3644/4885HCRTR2 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.